Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma.

MLA

M. D., Michaelson, et al. “Phase 2 Trial of Sunitinib and Gemcitabine in Patients with Sarcomatoid and/or Poor-Risk Metastatic Renal Cell Carcinoma.” Urologic Oncology, vol. 35, no. 3, Mar. 2017, pp. 117–18. EBSCOhost, https://doi.org/10.1002/cncr.29503.

APA

M. D., M., R. R., M., L., W., M. B., A., E. M., V. A., K. M., O., J., S., S., S., D. F., M., & T. K., C. (2017). Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Urologic Oncology, 35(3), 117–118. https://doi.org/10.1002/cncr.29503

Chicago

M. D., Michaelson, McKay R. R., Werner L., Atkins M. B., Van Allen E. M., Olivier K. M., Song J., Signoretti S., McDermott D. F., and Choueiri T. K. 2017. “Phase 2 Trial of Sunitinib and Gemcitabine in Patients with Sarcomatoid and/or Poor-Risk Metastatic Renal Cell Carcinoma.” Urologic Oncology 35 (3): 117–18. doi:10.1002/cncr.29503.